Immediate bromodeoxyuridine labelling of unseparated human bone marrow cells ex vivo is superior to labelling after routine laboratory processing.
It is important to evaluate the proliferation of bone marrow cells in several disease conditions and during treatment of patients with for example cytokines. Labelling with bromodeoxyuridine (BrdUrd), immunocytochemical staining with anti-BrdUrd antibody and analysis by flow cytometry provides a reliable and reproducible technique for estimation of the fraction of cells that incorporated BrdUrd into DNA during S-phase. We have compared immediate BrdUrd labelling of unseparated bone marrow cells with the previously used labelling in the laboratory after routine separation of the mononuclear cells. Bone marrow aspirates from seven lymphoma patients without bone marrow involvement were studied with these two methods. We found higher BrdUrd labelling indices (LI) in the mononuclear cells, when cells were labelled immediately. A large variation in LI was found between patients. Our results suggest that ex vivo BrdUrd labelling of bone marrow cells should be performed immediately after aspiration and before separation, because these data are closer to values reported from in vivo labelling with BrdUrd.
Finsen Laboratory, Finsen Center, Rigshospitalet, Copenhagen University Hospital, Denmark.
P O
PO
Jensen
B T
BT
Mortensen
I J
IJ
Christensen
J K
JK
Larsen
D001854:Bone Marrow Cells / Q000166:cytology*; D001973:Bromodeoxyuridine; D002469:Cell Separation / Q000379:methods*; D005434:Flow Cytometry; D006801:Humans
D001973:Bromodeoxyuridine